FI68626C - Foerfarande foer framstaellning av nya terapeutiskt aktiva hydroxikarbonylfosfonsyraderivat - Google Patents

Foerfarande foer framstaellning av nya terapeutiskt aktiva hydroxikarbonylfosfonsyraderivat Download PDF

Info

Publication number: FI68626C
Authority: FI; Finland
Prior art keywords: viruses; viral; virus; adamant; nmr
Prior art date: 1977-12-22

Application number

FI783932A

Other languages

English (en)

Finnish (fi)

Swedish (sv)

Other versions

FI783932A7 (fi

FI68626B (fi

Inventor

Aoke John Helgstrand

Karl Nils-Gunnar Johansson

Alfons Misiorny

Jan-Olof Noren

Goeran Bertil Stening

Original Assignee

Astra Laekemedel Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-12-22

Filing date

1978-12-20

Publication date

1985-10-10

1978-12-20 Application filed by Astra Laekemedel Ab filed Critical Astra Laekemedel Ab

1979-06-23 Publication of FI783932A7 publication Critical patent/FI783932A7/fi

1985-06-28 Application granted granted Critical

1985-06-28 Publication of FI68626B publication Critical patent/FI68626B/fi

1985-10-10 Publication of FI68626C publication Critical patent/FI68626C/fi

Links

150000001875 compounds Chemical class 0.000 claims description 56
-1 hydroxycarbonylphosphonic acid triester Chemical class 0.000 claims description 37
239000000203 mixture Substances 0.000 claims description 30
150000003839 salts Chemical class 0.000 claims description 30
238000000034 method Methods 0.000 claims description 27
238000002360 preparation method Methods 0.000 claims description 22
ZJAOAACCNHFJAH-UHFFFAOYSA-N phosphonoformic acid Chemical class OC(=O)P(O)(O)=O ZJAOAACCNHFJAH-UHFFFAOYSA-N 0.000 claims description 13
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 9
125000001316 cycloalkyl alkyl group Chemical group 0.000 claims description 8
125000000753 cycloalkyl group Chemical group 0.000 claims description 8
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
230000008569 process Effects 0.000 claims description 7
125000000217 alkyl group Chemical group 0.000 claims description 6
230000003287 optical effect Effects 0.000 claims description 6
125000003808 silyl group Chemical group [H][Si]([H])([H])[*] 0.000 claims description 4
125000003107 substituted aryl group Chemical group 0.000 claims description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 62
241000700605 Viruses Species 0.000 description 59
206010028980 Neoplasm Diseases 0.000 description 44
238000006243 chemical reaction Methods 0.000 description 34
238000004458 analytical method Methods 0.000 description 33
230000003612 virological effect Effects 0.000 description 32
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 31
229920002477 rna polymer Polymers 0.000 description 27
108020004414 DNA Proteins 0.000 description 25
102000053602 DNA Human genes 0.000 description 25
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 24
239000013543 active substance Substances 0.000 description 24
210000004027 cell Anatomy 0.000 description 20
KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 20
CYTQBVOFDCPGCX-UHFFFAOYSA-N trimethyl phosphite Chemical compound COP(OC)OC CYTQBVOFDCPGCX-UHFFFAOYSA-N 0.000 description 20
201000011510 cancer Diseases 0.000 description 19
239000011734 sodium Substances 0.000 description 19
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 19
238000011282 treatment Methods 0.000 description 19
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
229910052751 metal Inorganic materials 0.000 description 18
239000002184 metal Substances 0.000 description 18
239000007858 starting material Substances 0.000 description 18
238000009472 formulation Methods 0.000 description 16
239000000243 solution Substances 0.000 description 16
241001529453 unidentified herpesvirus Species 0.000 description 16
230000000694 effects Effects 0.000 description 15
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 14
239000004480 active ingredient Substances 0.000 description 14
208000036142 Viral infection Diseases 0.000 description 13
239000002253 acid Substances 0.000 description 13
125000004185 ester group Chemical group 0.000 description 13
208000015181 infectious disease Diseases 0.000 description 13
230000009385 viral infection Effects 0.000 description 13
230000006870 function Effects 0.000 description 12
201000010099 disease Diseases 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
102000039446 nucleic acids Human genes 0.000 description 11
108020004707 nucleic acids Proteins 0.000 description 11
150000007523 nucleic acids Chemical class 0.000 description 11
229920002873 Polyethylenimine Polymers 0.000 description 10
230000000840 anti-viral effect Effects 0.000 description 10
229910052799 carbon Inorganic materials 0.000 description 10
239000008187 granular material Substances 0.000 description 10
239000000126 substance Substances 0.000 description 10
125000003118 aryl group Chemical group 0.000 description 9
238000002512 chemotherapy Methods 0.000 description 9
230000002068 genetic effect Effects 0.000 description 9
239000007924 injection Substances 0.000 description 9
238000002347 injection Methods 0.000 description 9
239000002244 precipitate Substances 0.000 description 9
239000000047 product Substances 0.000 description 9
239000007921 spray Substances 0.000 description 9
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
102000004190 Enzymes Human genes 0.000 description 8
108090000790 Enzymes Proteins 0.000 description 8
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 8
230000001413 cellular effect Effects 0.000 description 8
239000000463 material Substances 0.000 description 8
MEUIIHOXOWVKNP-UHFFFAOYSA-N phosphanylformic acid Chemical class OC(P)=O MEUIIHOXOWVKNP-UHFFFAOYSA-N 0.000 description 8
229910020175 SiOH Inorganic materials 0.000 description 7
229920002472 Starch Polymers 0.000 description 7
239000002775 capsule Substances 0.000 description 7
150000002148 esters Chemical class 0.000 description 7
239000002674 ointment Substances 0.000 description 7
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 7
239000008107 starch Substances 0.000 description 7
235000019698 starch Nutrition 0.000 description 7
239000000725 suspension Substances 0.000 description 7
238000004448 titration Methods 0.000 description 7
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 6
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
RYXPMWYHEBGTRV-UHFFFAOYSA-N Omeprazole sodium Chemical compound [Na+].N=1C2=CC(OC)=CC=C2[N-]C=1S(=O)CC1=NC=C(C)C(OC)=C1C RYXPMWYHEBGTRV-UHFFFAOYSA-N 0.000 description 6
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
206010039491 Sarcoma Diseases 0.000 description 6
VTYYLEPIZMXCLO-UHFFFAOYSA-L calcium carbonate Substances [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 6
229910002091 carbon monoxide Inorganic materials 0.000 description 6
239000013078 crystal Substances 0.000 description 6
208000032839 leukemia Diseases 0.000 description 6
MEFBJEMVZONFCJ-UHFFFAOYSA-N molybdate Chemical compound [O-][Mo]([O-])(=O)=O MEFBJEMVZONFCJ-UHFFFAOYSA-N 0.000 description 6
229920001223 polyethylene glycol Polymers 0.000 description 6
229910052708 sodium Inorganic materials 0.000 description 6
235000009518 sodium iodide Nutrition 0.000 description 6
230000001225 therapeutic effect Effects 0.000 description 6
230000000699 topical effect Effects 0.000 description 6
150000005691 triesters Chemical class 0.000 description 6
BDZBKCUKTQZUTL-UHFFFAOYSA-N triethyl phosphite Chemical compound CCOP(OCC)OCC BDZBKCUKTQZUTL-UHFFFAOYSA-N 0.000 description 6
241000712461 unidentified influenza virus Species 0.000 description 6
241001465754 Metazoa Species 0.000 description 5
241000277284 Salvelinus fontinalis Species 0.000 description 5
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
239000011575 calcium Substances 0.000 description 5
150000001768 cations Chemical class 0.000 description 5
238000000576 coating method Methods 0.000 description 5
239000003814 drug Substances 0.000 description 5
238000001914 filtration Methods 0.000 description 5
210000003128 head Anatomy 0.000 description 5
229910052740 iodine Inorganic materials 0.000 description 5
229910052749 magnesium Inorganic materials 0.000 description 5
XMJHPCRAQCTCFT-UHFFFAOYSA-N methyl chloroformate Chemical compound COC(Cl)=O XMJHPCRAQCTCFT-UHFFFAOYSA-N 0.000 description 5
230000001613 neoplastic effect Effects 0.000 description 5
238000001668 nucleic acid synthesis Methods 0.000 description 5
125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 5
239000008194 pharmaceutical composition Substances 0.000 description 5
239000007787 solid Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
DFHAXXVZCFXGOQ-UHFFFAOYSA-K trisodium phosphonoformate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)P([O-])([O-])=O DFHAXXVZCFXGOQ-UHFFFAOYSA-K 0.000 description 5
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 4
208000001688 Herpes Genitalis Diseases 0.000 description 4
208000004898 Herpes Labialis Diseases 0.000 description 4
206010062639 Herpes dermatitis Diseases 0.000 description 4
208000000903 Herpes simplex encephalitis Diseases 0.000 description 4
208000007514 Herpes zoster Diseases 0.000 description 4
241000282414 Homo sapiens Species 0.000 description 4
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
229930195725 Mannitol Natural products 0.000 description 4
208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 4
206010067152 Oral herpes Diseases 0.000 description 4
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 4
239000003443 antiviral agent Substances 0.000 description 4
229910052788 barium Inorganic materials 0.000 description 4
XFKFJOZJWXBAPK-UHFFFAOYSA-N benzyl dimethoxyphosphorylformate Chemical compound COP(=O)(OC)C(=O)OCC1=CC=CC=C1 XFKFJOZJWXBAPK-UHFFFAOYSA-N 0.000 description 4
230000015572 biosynthetic process Effects 0.000 description 4
244000309464 bull Species 0.000 description 4
125000002091 cationic group Chemical group 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
229940079593 drug Drugs 0.000 description 4
GUQVYDAFWJAQEF-UHFFFAOYSA-N ethyl 4-carbonochloridoyloxybenzoate Chemical compound CCOC(=O)C1=CC=C(OC(Cl)=O)C=C1 GUQVYDAFWJAQEF-UHFFFAOYSA-N 0.000 description 4
239000000499 gel Substances 0.000 description 4
239000007903 gelatin capsule Substances 0.000 description 4
201000004946 genital herpes Diseases 0.000 description 4
230000002401 inhibitory effect Effects 0.000 description 4
230000010354 integration Effects 0.000 description 4
206010023332 keratitis Diseases 0.000 description 4
239000008101 lactose Substances 0.000 description 4
239000011777 magnesium Substances 0.000 description 4
239000000594 mannitol Substances 0.000 description 4
235000010355 mannitol Nutrition 0.000 description 4
229910021645 metal ion Inorganic materials 0.000 description 4
229910052757 nitrogen Inorganic materials 0.000 description 4
239000003921 oil Substances 0.000 description 4
235000019198 oils Nutrition 0.000 description 4
239000000825 pharmaceutical preparation Substances 0.000 description 4
229910052700 potassium Inorganic materials 0.000 description 4
235000011181 potassium carbonates Nutrition 0.000 description 4
239000000843 powder Substances 0.000 description 4
238000011321 prophylaxis Methods 0.000 description 4
239000000600 sorbitol Substances 0.000 description 4
235000010356 sorbitol Nutrition 0.000 description 4
210000002784 stomach Anatomy 0.000 description 4
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
241001430294 unidentified retrovirus Species 0.000 description 4
229910052725 zinc Inorganic materials 0.000 description 4
239000011701 zinc Substances 0.000 description 4
229920000945 Amylopectin Polymers 0.000 description 3
208000011691 Burkitt lymphomas Diseases 0.000 description 3
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 3
229920002261 Corn starch Polymers 0.000 description 3
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
108010010803 Gelatin Proteins 0.000 description 3
208000029433 Herpesviridae infectious disease Diseases 0.000 description 3
102100034343 Integrase Human genes 0.000 description 3
206010025323 Lymphomas Diseases 0.000 description 3
206010061306 Nasopharyngeal cancer Diseases 0.000 description 3
ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 3
239000002202 Polyethylene glycol Substances 0.000 description 3
108010092799 RNA-directed DNA polymerase Proteins 0.000 description 3
208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 3
239000011668 ascorbic acid Substances 0.000 description 3
235000010323 ascorbic acid Nutrition 0.000 description 3
229960005070 ascorbic acid Drugs 0.000 description 3
235000010216 calcium carbonate Nutrition 0.000 description 3
230000000711 cancerogenic effect Effects 0.000 description 3
231100000315 carcinogenic Toxicity 0.000 description 3
201000010881 cervical cancer Diseases 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
239000006071 cream Substances 0.000 description 3
239000008273 gelatin Substances 0.000 description 3
229920000159 gelatin Polymers 0.000 description 3
235000019322 gelatine Nutrition 0.000 description 3
235000011852 gelatine desserts Nutrition 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
201000006747 infectious mononucleosis Diseases 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
229910052744 lithium Inorganic materials 0.000 description 3
YYWJIOYRAZIVMY-UHFFFAOYSA-N methyl [1-adamantyloxy(methoxy)phosphoryl]formate Chemical compound C1C(C2)CC3CC2CC1(OP(=O)(OC)C(=O)OC)C3 YYWJIOYRAZIVMY-UHFFFAOYSA-N 0.000 description 3
HEGJQRZSAFDZAW-UHFFFAOYSA-N methyl dibutoxyphosphorylformate Chemical compound CCCCOP(=O)(C(=O)OC)OCCCC HEGJQRZSAFDZAW-UHFFFAOYSA-N 0.000 description 3
201000011216 nasopharynx carcinoma Diseases 0.000 description 3
239000003960 organic solvent Substances 0.000 description 3
230000035515 penetration Effects 0.000 description 3
230000000144 pharmacologic effect Effects 0.000 description 3
229920000642 polymer Polymers 0.000 description 3
229910000027 potassium carbonate Inorganic materials 0.000 description 3
229920001592 potato starch Polymers 0.000 description 3
150000003242 quaternary ammonium salts Chemical class 0.000 description 3
238000003756 stirring Methods 0.000 description 3
239000001993 wax Substances 0.000 description 3
DKXJJTRYBPUAGO-UHFFFAOYSA-N (3,4-dichlorophenyl) dimethoxyphosphorylformate Chemical compound COP(=O)(OC)C(=O)OC1=CC=C(Cl)C(Cl)=C1 DKXJJTRYBPUAGO-UHFFFAOYSA-N 0.000 description 2
RYWGPCLTVXMMHO-UHFFFAOYSA-N (4-chlorophenyl) carbonochloridate Chemical compound ClC(=O)OC1=CC=C(Cl)C=C1 RYWGPCLTVXMMHO-UHFFFAOYSA-N 0.000 description 2
CCFSGQKTSBIIHG-UHFFFAOYSA-N (4-methoxyphenyl) carbonochloridate Chemical compound COC1=CC=C(OC(Cl)=O)C=C1 CCFSGQKTSBIIHG-UHFFFAOYSA-N 0.000 description 2
JXVODAWCJBNFSH-UHFFFAOYSA-N (4-methoxyphenyl) diethoxyphosphorylformate Chemical compound CCOP(=O)(OCC)C(=O)OC1=CC=C(OC)C=C1 JXVODAWCJBNFSH-UHFFFAOYSA-N 0.000 description 2
XOFZPIYYMJUNRG-UHFFFAOYSA-N (4-methylphenyl) carbonochloridate Chemical compound CC1=CC=C(OC(Cl)=O)C=C1 XOFZPIYYMJUNRG-UHFFFAOYSA-N 0.000 description 2
YHCKQPDMBOBZBH-UHFFFAOYSA-N (4-methylphenyl) dimethoxyphosphorylformate Chemical compound COP(=O)(OC)C(=O)OC1=CC=C(C)C=C1 YHCKQPDMBOBZBH-UHFFFAOYSA-N 0.000 description 2
DPEYHNFHDIXMNV-UHFFFAOYSA-N (9-amino-3-bicyclo[3.3.1]nonanyl)-(4-benzyl-5-methyl-1,4-diazepan-1-yl)methanone dihydrochloride Chemical compound Cl.Cl.CC1CCN(CCN1Cc1ccccc1)C(=O)C1CC2CCCC(C1)C2N DPEYHNFHDIXMNV-UHFFFAOYSA-N 0.000 description 2
YWMNJCBYJLUTHE-UHFFFAOYSA-N 1-adamantyl dimethyl phosphite Chemical compound C1C(C2)CC3CC2CC1(OP(OC)OC)C3 YWMNJCBYJLUTHE-UHFFFAOYSA-N 0.000 description 2
KPWDGTGXUYRARH-UHFFFAOYSA-N 2,2,2-trichloroethanol Chemical compound OCC(Cl)(Cl)Cl KPWDGTGXUYRARH-UHFFFAOYSA-N 0.000 description 2
WUVZDJSSAGWPIE-UHFFFAOYSA-N 2-adamantyl carbonochloridate Chemical compound C1C(C2)CC3CC1C(OC(=O)Cl)C2C3 WUVZDJSSAGWPIE-UHFFFAOYSA-N 0.000 description 2
SVVQWOVZZTVIBC-UHFFFAOYSA-N 2-adamantyl dimethoxyphosphorylformate Chemical compound C1C(C2)CC3CC1C(OC(=O)P(=O)(OC)OC)C2C3 SVVQWOVZZTVIBC-UHFFFAOYSA-N 0.000 description 2
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
241000712891 Arenavirus Species 0.000 description 2
208000026310 Breast neoplasm Diseases 0.000 description 2
229910014033 C-OH Inorganic materials 0.000 description 2
XLWDEYBNQLXURI-UHFFFAOYSA-N COP(=O)(C(=O)OCC12CC3CC(C1)CC(C3)C2)O Chemical compound COP(=O)(C(=O)OCC12CC3CC(C1)CC(C3)C2)O XLWDEYBNQLXURI-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
201000009030 Carcinoma Diseases 0.000 description 2
206010008342 Cervix carcinoma Diseases 0.000 description 2
241000711573 Coronaviridae Species 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
206010011831 Cytomegalovirus infection Diseases 0.000 description 2
229910014570 C—OH Inorganic materials 0.000 description 2
241000450599 DNA viruses Species 0.000 description 2
108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical class C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 2
229920003136 Eudragit® L polymer Polymers 0.000 description 2
229920003137 Eudragit® S polymer Polymers 0.000 description 2
206010019799 Hepatitis viral Diseases 0.000 description 2
208000017604 Hodgkin disease Diseases 0.000 description 2
241000701044 Human gammaherpesvirus 4 Species 0.000 description 2
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 2
241000713112 Orthobunyavirus Species 0.000 description 2
KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
206010035226 Plasma cell myeloma Diseases 0.000 description 2
229940124639 Selective inhibitor Drugs 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
229930006000 Sucrose Natural products 0.000 description 2
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 description 2
150000001298 alcohols Chemical class 0.000 description 2
150000004703 alkoxides Chemical class 0.000 description 2
150000003863 ammonium salts Chemical class 0.000 description 2
230000003321 amplification Effects 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
HSDAJNMJOMSNEV-UHFFFAOYSA-N benzyl chloroformate Chemical compound ClC(=O)OCC1=CC=CC=C1 HSDAJNMJOMSNEV-UHFFFAOYSA-N 0.000 description 2
210000000621 bronchi Anatomy 0.000 description 2
239000006172 buffering agent Substances 0.000 description 2
NRDQFWXVTPZZAZ-UHFFFAOYSA-N butyl carbonochloridate Chemical compound CCCCOC(Cl)=O NRDQFWXVTPZZAZ-UHFFFAOYSA-N 0.000 description 2
AVMOQPPSZHDSEA-UHFFFAOYSA-N butyl dimethoxyphosphorylformate Chemical compound CCCCOC(=O)P(=O)(OC)OC AVMOQPPSZHDSEA-UHFFFAOYSA-N 0.000 description 2
229910000019 calcium carbonate Inorganic materials 0.000 description 2
150000004649 carbonic acid derivatives Chemical class 0.000 description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
125000003262 carboxylic acid ester group Chemical group [H]C([H])([*:2])OC(=O)C([H])([H])[*:1] 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
239000003054 catalyst Substances 0.000 description 2
230000003915 cell function Effects 0.000 description 2
230000010307 cell transformation Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000007795 chemical reaction product Substances 0.000 description 2
IWVJLGPDBXCTDA-UHFFFAOYSA-N cyclohexyl carbonochloridate Chemical compound ClC(=O)OC1CCCCC1 IWVJLGPDBXCTDA-UHFFFAOYSA-N 0.000 description 2
150000003946 cyclohexylamines Chemical class 0.000 description 2
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
DDPRIBJJDYHQDB-UHFFFAOYSA-N cyclopentylmethyl carbonochloridate Chemical compound ClC(=O)OCC1CCCC1 DDPRIBJJDYHQDB-UHFFFAOYSA-N 0.000 description 2
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 2
KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical class [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 2
238000004821 distillation Methods 0.000 description 2
239000006196 drop Substances 0.000 description 2
239000003937 drug carrier Substances 0.000 description 2
238000001035 drying Methods 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
239000002702 enteric coating Substances 0.000 description 2
238000005886 esterification reaction Methods 0.000 description 2
HCCIYAQAHHSQLD-UHFFFAOYSA-N ethyl 4-diethoxyphosphorylcarbonyloxybenzoate Chemical compound CCOC(=O)C1=CC=C(OC(=O)P(=O)(OCC)OCC)C=C1 HCCIYAQAHHSQLD-UHFFFAOYSA-N 0.000 description 2
SBMTTXOCKLSCDZ-UHFFFAOYSA-N ethyl 4-dimethoxyphosphorylcarbonyloxybenzoate Chemical compound CCOC(=O)C1=CC=C(OC(=O)P(=O)(OC)OC)C=C1 SBMTTXOCKLSCDZ-UHFFFAOYSA-N 0.000 description 2
MSXLZDIUXZWZDO-UHFFFAOYSA-N ethyl diphenoxyphosphorylformate Chemical compound C=1C=CC=CC=1OP(=O)(C(=O)OCC)OC1=CC=CC=C1 MSXLZDIUXZWZDO-UHFFFAOYSA-N 0.000 description 2
210000004392 genitalia Anatomy 0.000 description 2
208000002672 hepatitis B Diseases 0.000 description 2
239000001257 hydrogen Substances 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
208000037797 influenza A Diseases 0.000 description 2
208000037798 influenza B Diseases 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
230000003993 interaction Effects 0.000 description 2
239000011630 iodine Substances 0.000 description 2
210000000867 larynx Anatomy 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
239000000314 lubricant Substances 0.000 description 2
229910052748 manganese Inorganic materials 0.000 description 2
239000011572 manganese Substances 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
150000002739 metals Chemical class 0.000 description 2
MLJVWFGPQCOELH-UHFFFAOYSA-N methyl diethoxyphosphorylformate Chemical compound CCOP(=O)(OCC)C(=O)OC MLJVWFGPQCOELH-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000000214 mouth Anatomy 0.000 description 2
239000007922 nasal spray Substances 0.000 description 2
229930014626 natural product Natural products 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
238000003199 nucleic acid amplification method Methods 0.000 description 2
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical class CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
239000012188 paraffin wax Substances 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
210000003899 penis Anatomy 0.000 description 2
AHWALFGBDFAJAI-UHFFFAOYSA-N phenyl carbonochloridate Chemical compound ClC(=O)OC1=CC=CC=C1 AHWALFGBDFAJAI-UHFFFAOYSA-N 0.000 description 2
230000026731 phosphorylation Effects 0.000 description 2
238000006366 phosphorylation reaction Methods 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
IVRIRQXJSNCSPQ-UHFFFAOYSA-N propan-2-yl carbonochloridate Chemical compound CC(C)OC(Cl)=O IVRIRQXJSNCSPQ-UHFFFAOYSA-N 0.000 description 2
TTYOCFPPDNHPRQ-UHFFFAOYSA-N propan-2-yl dimethoxyphosphorylformate Chemical compound COP(=O)(OC)C(=O)OC(C)C TTYOCFPPDNHPRQ-UHFFFAOYSA-N 0.000 description 2
230000000069 prophylactic effect Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002441 reversible effect Effects 0.000 description 2
239000003381 stabilizer Substances 0.000 description 2
239000005720 sucrose Substances 0.000 description 2
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
238000004809 thin layer chromatography Methods 0.000 description 2
239000004408 titanium dioxide Substances 0.000 description 2
230000009466 transformation Effects 0.000 description 2
XTTGYFREQJCEML-UHFFFAOYSA-N tributyl phosphite Chemical compound CCCCOP(OCCCC)OCCCC XTTGYFREQJCEML-UHFFFAOYSA-N 0.000 description 2
WZCZNEGTXVXAAS-UHFFFAOYSA-N trifluoromethanol Chemical compound OC(F)(F)F WZCZNEGTXVXAAS-UHFFFAOYSA-N 0.000 description 2
125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
230000000381 tumorigenic effect Effects 0.000 description 2
210000003932 urinary bladder Anatomy 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
230000029812 viral genome replication Effects 0.000 description 2
201000001862 viral hepatitis Diseases 0.000 description 2
210000003905 vulva Anatomy 0.000 description 2
ZDTLCBPNKGXDMA-UHFFFAOYSA-N (3,4-dichlorophenyl) carbonochloridate Chemical compound ClC(=O)OC1=CC=C(Cl)C(Cl)=C1 ZDTLCBPNKGXDMA-UHFFFAOYSA-N 0.000 description 1
UPNZNUZWFKDCQK-UHFFFAOYSA-N (4-chlorophenyl) diethoxyphosphorylformate Chemical compound CCOP(=O)(OCC)C(=O)OC1=CC=C(Cl)C=C1 UPNZNUZWFKDCQK-UHFFFAOYSA-N 0.000 description 1
YHZSRQZZRREBDQ-UHFFFAOYSA-N (4-methoxyphenoxy)carbonylphosphonic acid Chemical compound COC1=CC=C(OC(=O)P(O)(O)=O)C=C1 YHZSRQZZRREBDQ-UHFFFAOYSA-N 0.000 description 1
UOCLXMDMGBRAIB-UHFFFAOYSA-N 1,1,1-trichloroethane Chemical compound CC(Cl)(Cl)Cl UOCLXMDMGBRAIB-UHFFFAOYSA-N 0.000 description 1
244000215068 Acacia senegal Species 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
235000003911 Arachis Nutrition 0.000 description 1
244000105624 Arachis hypogaea Species 0.000 description 1
241001160050 Bat mastadenovirus Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical class OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
241000283690 Bos taurus Species 0.000 description 1
206010006187 Breast cancer Diseases 0.000 description 1
206010006417 Bronchial carcinoma Diseases 0.000 description 1
JRYMNZMLTJLORZ-UHFFFAOYSA-N C1C(=CC=CC1(Cl)Cl)OC(=O)Cl Chemical compound C1C(=CC=CC1(Cl)Cl)OC(=O)Cl JRYMNZMLTJLORZ-UHFFFAOYSA-N 0.000 description 1
YULARKBZWBMPFP-UHFFFAOYSA-N CC(C)(C1CCCC1)OC(=O)P(=O)(O)O Chemical compound CC(C)(C1CCCC1)OC(=O)P(=O)(O)O YULARKBZWBMPFP-UHFFFAOYSA-N 0.000 description 1
OEHJEBPMNHXWLJ-UHFFFAOYSA-N CC1(CCC(CC1)OC(=O)P(=O)(O)O)C Chemical compound CC1(CCC(CC1)OC(=O)P(=O)(O)O)C OEHJEBPMNHXWLJ-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
UGFAIRIUMAVXCW-UHFFFAOYSA-N Carbon monoxide Chemical compound [O+]#[C-] UGFAIRIUMAVXCW-UHFFFAOYSA-N 0.000 description 1
229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
101150096040 GNAO1 gene Proteins 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
241000412298 Harma Species 0.000 description 1
241000700721 Hepatitis B virus Species 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
208000009889 Herpes Simplex Diseases 0.000 description 1
208000010747 Hodgkins lymphoma Diseases 0.000 description 1
241000282412 Homo Species 0.000 description 1
241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
241000701074 Human alphaherpesvirus 2 Species 0.000 description 1
241000701372 Iridovirus Species 0.000 description 1
241001466453 Laminaria Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
UIHCLUNTQKBZGK-UHFFFAOYSA-N Methyl isobutyl ketone Natural products CCC(C)C(C)=O UIHCLUNTQKBZGK-UHFFFAOYSA-N 0.000 description 1
208000034578 Multiple myelomas Diseases 0.000 description 1
241000702244 Orthoreovirus Species 0.000 description 1
101001077374 Oryza sativa subsp. japonica UMP-CMP kinase 3 Proteins 0.000 description 1
PTPSESCCTXFCGE-UHFFFAOYSA-N P1(OOC(=O)O1)=O.[Na].[Na].[Na] Chemical compound P1(OOC(=O)O1)=O.[Na].[Na].[Na] PTPSESCCTXFCGE-UHFFFAOYSA-N 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001631646 Papillomaviridae Species 0.000 description 1
OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
241000709664 Picornaviridae Species 0.000 description 1
241000125945 Protoparvovirus Species 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
241000702263 Reovirus sp. Species 0.000 description 1
229910008329 Si-V Inorganic materials 0.000 description 1
229910006768 Si—V Inorganic materials 0.000 description 1
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
241000011102 Thera Species 0.000 description 1
241001232874 Tunga Species 0.000 description 1
229910052770 Uranium Inorganic materials 0.000 description 1
IILFHLZETDXMIN-UHFFFAOYSA-L [O-]P(C(OCC1(CC(C2)C3)CC3CC2C1)=O)([O-])=O.[Na+].[Na+] Chemical compound [O-]P(C(OCC1(CC(C2)C3)CC3CC2C1)=O)([O-])=O.[Na+].[Na+] IILFHLZETDXMIN-UHFFFAOYSA-L 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
239000012190 activator Substances 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000004479 aerosol dispenser Substances 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
239000000538 analytical sample Substances 0.000 description 1
229940124977 antiviral medication Drugs 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
239000007844 bleaching agent Substances 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
208000003362 bronchogenic carcinoma Diseases 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001364 causal effect Effects 0.000 description 1
108091092356 cellular DNA Proteins 0.000 description 1
239000001913 cellulose Chemical class 0.000 description 1
229920002678 cellulose Chemical class 0.000 description 1
229940081734 cellulose acetate phthalate Drugs 0.000 description 1
210000003679 cervix uteri Anatomy 0.000 description 1
210000000038 chest Anatomy 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960004106 citric acid Drugs 0.000 description 1
235000020971 citrus fruits Nutrition 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000012043 crude product Substances 0.000 description 1
ZCIOCIWGLSMXNS-UHFFFAOYSA-N cyclohexyl dimethoxyphosphorylformate Chemical compound COP(=O)(OC)C(=O)OC1CCCCC1 ZCIOCIWGLSMXNS-UHFFFAOYSA-N 0.000 description 1
230000006378 damage Effects 0.000 description 1
238000007257 deesterification reaction Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
238000009826 distribution Methods 0.000 description 1
239000000975 dye Substances 0.000 description 1
239000007911 effervescent powder Substances 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000012055 enteric layer Substances 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
230000032050 esterification Effects 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
239000003889 eye drop Substances 0.000 description 1
229940012356 eye drops Drugs 0.000 description 1
210000000887 face Anatomy 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
210000004211 gastric acid Anatomy 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
208000019622 heart disease Diseases 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
208000006454 hepatitis Diseases 0.000 description 1
231100000283 hepatitis Toxicity 0.000 description 1
125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000010410 layer Substances 0.000 description 1
210000000088 lip Anatomy 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
238000011068 loading method Methods 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Substances [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
210000005075 mammary gland Anatomy 0.000 description 1
201000001441 melanoma Diseases 0.000 description 1
210000002418 meninge Anatomy 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
150000002736 metal compounds Chemical class 0.000 description 1
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical compound [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
231100000219 mutagenic Toxicity 0.000 description 1
230000003505 mutagenic effect Effects 0.000 description 1
GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Chemical class CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
239000007923 nasal drop Substances 0.000 description 1
229940100662 nasal drops Drugs 0.000 description 1
210000005170 neoplastic cell Anatomy 0.000 description 1
210000001331 nose Anatomy 0.000 description 1
TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000037361 pathway Effects 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
ZLTYWIDYZFPWLI-UHFFFAOYSA-N phenyl dimethoxyphosphorylformate Chemical compound COP(=O)(OC)C(=O)OC1=CC=CC=C1 ZLTYWIDYZFPWLI-UHFFFAOYSA-N 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
125000005496 phosphonium group Chemical group 0.000 description 1
125000005499 phosphonyl group Chemical group 0.000 description 1
229960002034 pinazepam Drugs 0.000 description 1
239000004014 plasticizer Substances 0.000 description 1
239000011591 potassium Substances 0.000 description 1
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
239000011241 protective layer Substances 0.000 description 1
ALZOLUNSQWINIR-UHFFFAOYSA-N quinmerac Chemical compound OC(=O)C1=C(Cl)C=CC2=CC(C)=CN=C21 ALZOLUNSQWINIR-UHFFFAOYSA-N 0.000 description 1
239000012429 reaction media Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
210000000664 rectum Anatomy 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
238000010992 reflux Methods 0.000 description 1
238000010839 reverse transcription Methods 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
239000000523 sample Substances 0.000 description 1
239000000741 silica gel Substances 0.000 description 1
229910002027 silica gel Inorganic materials 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 1
235000011182 sodium carbonates Nutrition 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
WXDSCXXENAZUJG-UHFFFAOYSA-M sodium;1-adamantyloxy(methoxycarbonyl)phosphinate Chemical compound [Na+].C1C(C2)CC3CC2CC1(OP([O-])(=O)C(=O)OC)C3 WXDSCXXENAZUJG-UHFFFAOYSA-M 0.000 description 1
MSFWPPJYESXYPI-UHFFFAOYSA-M sodium;butoxy(methoxycarbonyl)phosphinate Chemical compound [Na+].CCCCOP([O-])(=O)C(=O)OC MSFWPPJYESXYPI-UHFFFAOYSA-M 0.000 description 1
HSFQBFMEWSTNOW-UHFFFAOYSA-N sodium;carbanide Chemical group [CH3-].[Na+] HSFQBFMEWSTNOW-UHFFFAOYSA-N 0.000 description 1
VLGUOEHLZNBDNO-UHFFFAOYSA-M sodium;ethoxy(ethoxycarbonyl)phosphinate Chemical compound [Na+].CCOC(=O)P([O-])(=O)OCC VLGUOEHLZNBDNO-UHFFFAOYSA-M 0.000 description 1
PTLYWFMPCOFHDO-UHFFFAOYSA-M sodium;methoxy(phenylmethoxycarbonyl)phosphinate Chemical compound [Na+].COP([O-])(=O)C(=O)OCC1=CC=CC=C1 PTLYWFMPCOFHDO-UHFFFAOYSA-M 0.000 description 1
241000894007 species Species 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
210000001562 sternum Anatomy 0.000 description 1
230000002311 subsequent effect Effects 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
239000003826 tablet Substances 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
229960001367 tartaric acid Drugs 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical class CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
210000001685 thyroid gland Anatomy 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
210000002105 tongue Anatomy 0.000 description 1
238000011200 topical administration Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
230000014723 transformation of host cell by virus Effects 0.000 description 1
SOBHUZYZLFQYFK-UHFFFAOYSA-K trisodium;hydroxy-[[phosphonatomethyl(phosphonomethyl)amino]methyl]phosphinate Chemical compound [Na+].[Na+].[Na+].OP(O)(=O)CN(CP(O)([O-])=O)CP([O-])([O-])=O SOBHUZYZLFQYFK-UHFFFAOYSA-K 0.000 description 1
210000004881 tumor cell Anatomy 0.000 description 1
241000701161 unidentified adenovirus Species 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
210000004291 uterus Anatomy 0.000 description 1
238000010792 warming Methods 0.000 description 1
238000005406 washing Methods 0.000 description 1
150000003751 zinc Chemical class 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3886—Acids containing the structure -C(=X)-P(=X)(XH)2 or NC-P(=X)(XH)2, (X = O, S, Se)
- C07F9/3891—Acids containing the structure -C(=X)-P(=X)(XH)2, (X = O, S, Se)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/40—Esters thereof
- C07F9/4003—Esters thereof the acid moiety containing a substituent or a structure which is considered as characteristic
- C07F9/4062—Esters of acids containing the structure -C(=X)-P(=X)(XR)2 or NC-P(=X)(XR)2, (X = O, S, Se)
- C07F9/4065—Esters of acids containing the structure -C(=X)-P(=X)(XR)2, (X = O, S, Se)

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
General Health & Medical Sciences (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Virology (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

FI783932A 1977-12-22 1978-12-20 Foerfarande foer framstaellning av nya terapeutiskt aktiva hydroxikarbonylfosfonsyraderivat FI68626C (fi)

Applications Claiming Priority (16)

Application Number	Priority Date	Filing Date	Title
GB5358377		1977-12-22
GB5358177		1977-12-22
GB5358277		1977-12-22
GB5358277		1977-12-22
GB5358077		1977-12-22
GB5358377		1977-12-22
GB5358077		1977-12-22
GB5358177		1977-12-22
GB7828548		1978-07-03
GB7828552		1978-07-03
GB7828555		1978-07-03
GB7828552		1978-07-03
GB7828548		1978-07-03
GB7828555		1978-07-03
GB7828553		1978-07-03
GB7828553		1978-07-03

Publications (3)

Publication Number	Publication Date
FI783932A7 FI783932A7 (fi)	1979-06-23
FI68626B FI68626B (fi)	1985-06-28
FI68626C true FI68626C (fi)	1985-10-10

Family

ID=27571200

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
FI783931A FI65438C (fi)	1977-12-22	1978-12-20	Foerfarande foer framstaellning av farmakologiskt aktiva estrar av fosfonomyrsyra
FI783932A FI68626C (fi)	1977-12-22	1978-12-20	Foerfarande foer framstaellning av nya terapeutiskt aktiva hydroxikarbonylfosfonsyraderivat

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
FI783931A FI65438C (fi)	1977-12-22	1978-12-20	Foerfarande foer framstaellning av farmakologiskt aktiva estrar av fosfonomyrsyra

Country Status (14)

Country	Link
US (4)	US4386081A (da)
EP (2)	EP0003275B1 (da)
JP (2)	JPS54109951A (da)
AT (1)	AT369017B (da)
AU (1)	AU530031B2 (da)
CA (2)	CA1144937A (da)
DE (2)	DE2861729D1 (da)
DK (2)	DK148632C (da)
FI (2)	FI65438C (da)
HK (1)	HK33584A (da)
IE (1)	IE48011B1 (da)
MY (1)	MY8500058A (da)
NO (2)	NO156611C (da)
SG (1)	SG82383G (da)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1144937A (en) *	1977-12-22	1983-04-19	Dke J.E. Helgstrand	Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections
GB8501374D0 (en) *	1985-01-18	1985-02-20	Wellcome Found	Treatment of aids
US4806532A (en) *	1985-10-08	1989-02-21	Mayo Foundation For Medical Education And Research	Inhibition of epithelial phosphate transport
US6492352B1 (en) *	1985-10-31	2002-12-10	Astra Lakemedel Aktiebolag	Method for the control and treatment of acquired immunodeficiency syndrome (AIDS)
US5025003A (en) *	1989-09-18	1991-06-18	E. R. Squibb & Sons, Inc.	Isoprenoid phosphinylformic acid squalene synthetase inhibitors
US5166386A (en) *	1989-09-18	1992-11-24	E. R. Squibb & Sons, Inc.	Process of making isoprenoid phosphinylformic acid squalene synthetase inhibitors
US5463092A (en) *	1989-11-22	1995-10-31	Vestar, Inc.	Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US5132414A (en) *	1990-05-10	1992-07-21	Dana-Farber Cancer Institute, Inc.	Dideoxynucleoside-5'-phosphonoformic acid compounds
US5696277A (en) *	1994-11-15	1997-12-09	Karl Y. Hostetler	Antiviral prodrugs
US7517858B1 (en)	1995-06-07	2009-04-14	The Regents Of The University Of California	Prodrugs of pharmaceuticals with improved bioavailability
US6096730A (en) *	1997-07-24	2000-08-01	University Of Kentucky Research Foundation	Phosphonated agents and their antiangiogenic and antitumorigenic use
US5869469A (en) *	1997-08-18	1999-02-09	Queen's University At Kingston	Phosphonocarboxylate compounds for treating amyloidosis
NZ550116A (en) *	1997-08-18	2008-03-28	Neurochem Int Ltd	Phosphono-carboxylate compounds for treating amyloidosis
US20020022657A1 (en) *	1998-02-11	2002-02-21	Francine Gervais	Methods for modulating neuronal cell death
US20040002079A1 (en) *	1998-02-11	2004-01-01	Gunn Robert B.	Sodium-phosphate cotransporter in lithium therapy for the treatment of mental illness
WO1999040909A1 (en) *	1998-02-11	1999-08-19	Neurochem, Inc.	Method for modulating macrophage activation
US6329356B1 (en)	1998-04-10	2001-12-11	Neurochem, Inc.	Phosphono-carboxylate compounds for treating amyloidosis
US6310073B1 (en)	1998-07-28	2001-10-30	Queen's University At Kingston	Methods and compositions to treat glycosaminoglycan-associated molecular interactions
CA2369997C (en) *	1999-04-28	2009-11-17	Queen's University At Kingston	Compositions and methods for treating amyloidosis
US6562836B1 (en)	1999-05-24	2003-05-13	Queen's University Of Kingston	Methods and compounds for inhibiting amyloid deposits
IL150374A0 (en)	1999-12-23	2002-12-01	Neurochem Inc	Compounds and methods for modulating cerebral amyloid angiopathy
ATE337309T1 (de) *	2002-04-01	2006-09-15	Pfizer	Pyranon- und pyrandioninhibitoren der rna- abhängigen rna-polymerase des hepatitis-c-virus
DOP2003000641A (es) *	2002-05-10	2003-11-15	Pfizer	Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
US7148226B2 (en) *	2003-02-21	2006-12-12	Agouron Pharmaceuticals, Inc.	Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
US20040214178A1 (en) *	2003-04-24	2004-10-28	Agouron Pharmaceuticals, Inc.	Reporter-selectable Hepatitis C virus replicon
US20070010573A1 (en)	2003-06-23	2007-01-11	Xianqi Kong	Methods and compositions for treating amyloid-related diseases
US7414076B2 (en)	2003-06-23	2008-08-19	Neurochem (International) Limited	Methods and compositions for treating amyloid-related diseases
US7244764B2 (en)	2003-06-23	2007-07-17	Neurochem (International) Limited	Methods and compositions for treating amyloid-related diseases
UA88909C2 (ru) *	2004-08-18	2009-12-10	Пфайзер Инк.	Ингибиторы рнк-зависимой рнк-полимеразы вируса гепатита с, фармацевтическая композиция на их основе и их применение
ITMI20041822A1 (it) *	2004-09-24	2004-12-24	Pharmaproducts Uk Ltd	"agente terapeutico utile per il trattamento di neoplasie plasmacellulari"
US20060167057A1 (en) *	2004-11-16	2006-07-27	Xianqi Kong	Compounds for the treatment of CNS and amyloid associated diseases
WO2006085149A2 (en)	2004-12-22	2006-08-17	Neurochem (International) Limited	Methods and compositions for treating amyloid-related diseases
EP1968561B8 (en) *	2005-12-22	2010-10-20	Kiacta Sàrl	Treatment of diabetic nephropathy
PT2089417E (pt)	2006-10-12	2015-04-14	Bhi Ltd Partnership	Métodos, compostos, composições e veículos para administrar o ácido 3-amino-1-propanossulfónico
WO2008078176A1 (en) *	2006-12-22	2008-07-03	Bellus Health (International) Limited	Methods, compounds, and compositions for treating metabolic disorders and diabetes
US20080293648A1 (en) *	2007-01-05	2008-11-27	Saha Pharmaceuticals, Inc.	Compositions and Methods for Cancer Treatment
DE102012103717A1 (de) *	2012-04-27	2013-11-14	Westfälische Wilhelms-Universität Münster	Arzneimittel zur Behandlung von Tumorerkrankungen
WO2015093091A1 (ja) *	2013-12-19	2015-06-25	宇部興産株式会社	非水電解液、それを用いた蓄電デバイス、及びそれに用いられるホスホノぎ酸化合物
ES2578902B1 (es) *	2014-12-29	2017-07-07	Agencia Pública Empresarial Sanitaria Costa Del Sol	Uso de análogos del ión pirofosfato para el tratamiento de la infección por VPH
CN109400645A (zh) *	2017-08-18	2019-03-01	四川海思科制药有限公司	一种磷酸衍生物及制备方法和用途
WO2025106974A1 (en) *	2023-11-17	2025-05-22	The Board Of Trustees Of The Leland Stanford Junior University	Prodrug moieties and compounds comprising the same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3155597A (en) *	1961-06-23	1964-11-03	Monsanto Co	Extractive separation process
CH513590A (de)	1968-05-24	1971-10-15	Du Pont	Carbamoylphosphonat enthaltender Pflanzenwachstumsregler
US3997544A (en) *	1968-05-24	1976-12-14	E. I. Du Pont De Nemours And Company	Plant growth regulant carbamoylphosphonates
US3846512A (en) *	1968-05-24	1974-11-05	Du Pont	Carbamoylphosphonates
US3533995A (en) *	1968-08-27	1970-10-13	Fmc Corp	Heat stabilization of polyester resin with alkyl dialkoxyphosphinyl formate
GB1317768A (en)	1969-08-14	1973-05-23	Du Pont	Plant growth regulants
US3849102A (en) *	1969-08-14	1974-11-19	Du Pont	Plant growth regulant method
US3767795A (en) *	1971-02-25	1973-10-23	Abbott Lab	Method for combating certain virus infection
HU171255B (hu)	1973-07-23	1977-12-28	Du Pont	Kompozicii dlja regulirovki rosta rastenijj
US3943201A (en) *	1973-07-23	1976-03-09	E. I. Du Pont De Nemours And Comapny	Alkoxy carboxycarbonylphosphonic acid esters
US4017297A (en) *	1975-08-29	1977-04-12	E. I. Du Pont De Nemours And Company	Phosphonates for the control of bindweed
US4092412A (en) *	1976-04-30	1978-05-30	Abbott Laboratories	Treatment of herpes simplex infections
CA1069526A (en) *	1976-04-30	1980-01-08	Thomas R. Herrin	Phosphorus esters of phosphonoacetic acid
US4052439A (en) *	1976-04-30	1977-10-04	Abbott Laboratories	Carboxylic esters of phosphonoacetic acid
SE7607496L (sv) *	1976-07-01	1978-01-02	Astra Laekemedel Ab	Sett for bekempning av virusinfektioner
CA1144937A (en) *	1977-12-22	1983-04-19	Dke J.E. Helgstrand	Aromatic derivatives, pharmaceutical compositions and methods for combatting virus infections

1978
- 1978-12-06 CA CA000317520A patent/CA1144937A/en not_active Expired
- 1978-12-06 CA CA000317487A patent/CA1140049A/en not_active Expired
- 1978-12-15 DK DK564278A patent/DK148632C/da not_active IP Right Cessation
- 1978-12-15 DK DK564178A patent/DK148631C/da not_active IP Right Cessation
- 1978-12-18 IE IE2493/78A patent/IE48011B1/en not_active IP Right Cessation
- 1978-12-19 DE DE7878850028T patent/DE2861729D1/de not_active Expired
- 1978-12-19 DE DE7878850027T patent/DE2861045D1/de not_active Expired
- 1978-12-19 AU AU42682/78A patent/AU530031B2/en not_active Expired
- 1978-12-19 EP EP78850027A patent/EP0003275B1/en not_active Expired
- 1978-12-19 EP EP78850028A patent/EP0003007B1/en not_active Expired
- 1978-12-20 FI FI783931A patent/FI65438C/fi not_active IP Right Cessation
- 1978-12-20 FI FI783932A patent/FI68626C/fi not_active IP Right Cessation
- 1978-12-21 NO NO784331A patent/NO156611C/no unknown
- 1978-12-21 NO NO784330A patent/NO154751C/no unknown
- 1978-12-22 AT AT0921778A patent/AT369017B/de not_active IP Right Cessation
- 1978-12-22 JP JP15839878A patent/JPS54109951A/ja active Granted
- 1978-12-22 JP JP15839978A patent/JPS54106431A/ja active Granted
1979
- 1979-11-13 US US06/093,167 patent/US4386081A/en not_active Expired - Lifetime
- 1979-11-13 US US06/093,166 patent/US4372894A/en not_active Expired - Lifetime
1982
- 1982-09-10 US US06/416,632 patent/US4536400A/en not_active Expired - Lifetime
- 1982-12-17 US US06/450,656 patent/US4591583A/en not_active Expired - Fee Related
1983
- 1983-12-23 SG SG823/83A patent/SG82383G/en unknown
1984
- 1984-04-18 HK HK335/84A patent/HK33584A/en not_active IP Right Cessation
1985
- 1985-12-30 MY MY58/85A patent/MY8500058A/xx unknown

Also Published As

Publication number	Publication date
JPS6330885B2 (da)	1988-06-21
DK564178A (da)	1979-06-23
EP0003275B1 (en)	1981-09-02
DK564278A (da)	1979-06-23
DK148631C (da)	1986-03-03
JPS6254118B2 (da)	1987-11-13
DE2861729D1 (en)	1982-05-19
EP0003007A3 (en)	1979-08-08
US4591583A (en)	1986-05-27
NO784331L (no)	1979-06-25
NO154751B (no)	1986-09-08
JPS54109951A (en)	1979-08-29
NO784330L (no)	1979-06-25
DK148632B (da)	1985-08-19
IE782493L (en)	1979-06-22
NO156611C (no)	1987-10-21
NO154751C (no)	1986-12-17
DK148631B (da)	1985-08-19
NO156611B (no)	1987-07-13
FI783932A7 (fi)	1979-06-23
FI68626B (fi)	1985-06-28
FI65438C (fi)	1984-05-10
DE2861045D1 (en)	1981-11-26
IE48011B1 (en)	1984-09-05
DK148632C (da)	1986-03-03
HK33584A (en)	1984-04-27
US4386081A (en)	1983-05-31
SG82383G (en)	1985-03-08
FI783931A7 (fi)	1979-06-23
FI65438B (fi)	1984-01-31
AT369017B (de)	1982-11-25
CA1144937A (en)	1983-04-19
JPS54106431A (en)	1979-08-21
AU4268278A (en)	1979-06-28
EP0003007B1 (en)	1982-04-07
CA1140049A (en)	1983-01-25
AU530031B2 (en)	1983-06-30
US4372894A (en)	1983-02-08
MY8500058A (en)	1985-12-31
EP0003275A1 (en)	1979-08-08
ATA921778A (de)	1982-04-15
US4536400A (en)	1985-08-20
EP0003007A2 (en)	1979-07-11

Legal Events

Date	Code	Title	Description
1997-12-20	MM	Patent lapsed
2004-08-31	MM	Patent lapsed	Owner name: ASTRA LAEKEMEDEL AB

Publication	Publication Date	Title
FI68626C (fi)	1985-10-10	Foerfarande foer framstaellning av nya terapeutiskt aktiva hydroxikarbonylfosfonsyraderivat
US10252974B2 (en)	2019-04-09	Cationic lipid
JP4980715B2 (ja)	2012-07-18	がんまたはウイルス疾患を治療するための三環性複素環化合物、組成物および方法
TWI630201B (zh)	2018-07-21	化合物及其調節血紅素之用途
CA2001715C (en)	1999-12-28	Carbocyclic nucleosides and nucleotides
BG60834B2 (bg)	1996-04-30	Фармацевтични състави на базата на фосфономравчена киселина и приложението им
CN103435672A (zh)	2013-12-11	含有取代苄基的新型核苷磷酸酯前药的结构与合成
JP2002511406A (ja)	2002-04-16	感染症の治療および予防処置のための有機リン化合物の使用
EA008775B1 (ru)	2007-08-31	Ингибиторы протеазы вич для лечения инфекции вич и фармацевтическая композиция
KR20150046315A (ko)	2015-04-29	테노포비르 전구약물 및 그의 약학적 용도
US20190192547A1 (en)	2019-06-27	Gemcitabine protide hypoxia-activated prodrug and application thereof
Aaron et al.	1962	The Stereochemistry of Asymmetric Phosphorus Compounds. IV. The Synthesis and Stereochemistry of Displacement Reactions of Optically Active Isopropyl Methylphosphonochloridate
CA1085833A (en)	1980-09-16	Carboxylic esters of phosphonoacetic acid
Ford et al.	2022	Synthesis and evaluation of prodrugs of α-carboxy nucleoside phosphonates
CN1331695A (zh)	2002-01-16	有机磷化合物及其用途
US7420000B2 (en)	2008-09-02	Amino phosphonate and amino bis-phosphonate derivatives
NO784332L (no)	1979-06-25	Amidderivater, farmasoeytiske preparater og fremgangsmaate til bekjempelse av virusinfeksjoner
KR840002462B1 (ko)	1984-12-29	아릴알킬-및 아릴옥시알킬포스포네이트의 제조방법
FI65261C (fi)	1984-04-10	Foerfarande foer framstaellning av farmakologiskt anvaendbart dinatriumsalt av n-(fosfonoacetyl)-l-asparaginsyra
KR840002464B1 (ko)	1984-12-29	지방족 포스포노포름산 모노에스테르의 제조방법
Glabe	1995	The synthesis of novel epoxyacylphosphonates designed to inhibit HIV-1 reverse transcriptase
US4267126A (en)	1981-05-12	N-(Phosphonoacetyl)-L-aspartic acid compounds
Landers	2021	The Synthesis of Optically Active Phosphosphoramidates and Their Use in the Therapeutic Treament of Viral Infections
CN121627784A (zh)	2026-03-10	类嘌呤核苷磷酰胺酯zl-492及其在抗病毒药物中的应用
AT369016B (de)	1982-11-25	Verfahren zur herstellung neuer hydroxycarbonyl- phosphonsaeurederivate sowie von deren physiologisch akzeptablen salzen und optischen antipoden